Eli Lilly Signs $1.1B AI Drug Delivery Deal with METiS Therapeutics

Key Facts

1Eli Lilly signed a collaboration agreement with METiS Therapeutics to develop drug delivery technologies using artificial intelligence.

2The total potential value of the deal reaches up to $1.1 billion, including upfront payments and developmental milestones.

Eli Lilly signed a collaboration agreement with METiS Therapeutics to develop drug delivery technologies using artificial intelligence. Reuters reported that the total potential value of the deal reaches up to $1.1 billion, including upfront payments and developmental milestones.

The partnership aims to utilize METiS's AI and machine learning capabilities to optimize the delivery of Lilly's therapeutic pipeline. LLY closed at $1240.34 on October 19, 2026, after reaching a day high of $1259.75 during that session.